DoseMe Pty Ltd.

DoseMe Pty Ltd. specializes in advanced Bayesian dosing solutions that enhance therapeutic drug monitoring, enabling healthcare professionals to personalize drug administration for improved patient outcomes. Founded in 2012 and headquartered in Brisbane, Australia, DoseMe Pty Ltd. develops innovative solutions for therapeutic drug monitoring.

The company has engaged in a total of 4 deals with its most recent deal occurring on January 20, 2023. In January 2023, Fairlong Capital acquired DoseMe Pty Ltd. from Tabula Rasa HealthCare, Inc. , Radius Ventures, and Originate Ventures.

The company's leadership includes CEO Charles Cornish and Paul Edwards. To date, DoseMe has raised a total of USD 2. 60 mn, with its latest funding round being an Add-on, Trade Sale led by Tabula Rasa HealthCare, Inc. totaling USD 20.

00 mn. DoseMeRx offers a Bayesian dosing platform designed to facilitate precise therapeutic drug monitoring (TDM). This platform simplifies the complexities of individualized drug dosing, allowing clinicians to calculate doses based on a single serum level, thus enhancing patient safety and treatment efficacy. The platform supports various drug models, including those for vancomycin, oncology, transplant medicine, cardiovascular and coagulation management, and pediatrics.

DoseMeRx caters to clinical pharmacists, hospitals, and healthcare systems in the United States, Australia, and Europe, ensuring a comprehensive presence in the medical field. DoseMeRx generates revenue through a subscription-based model, providing healthcare institutions and practitioners access to its dosing platform. Clients typically engage in annual or multi-year subscriptions that include access to drug models, analytics tools, and support services. The DoseMeRx platform underpins the company's revenue strategy by enabling better clinical decision-making and patient outcomes.

Its integration capabilities foster collaboration among healthcare teams, driving utilization and renewal of subscriptions, which supports the financial stability of the company. Following the recent acquisition completed on January 20, 2023, DoseMe Pty Ltd. plans to leverage the additional resources to develop solutions aimed at optimizing the dosing of narrow therapeutic index drugs. This initiative is expected to enhance patient outcomes and support healthcare organizations.

The company is focused on expanding its market reach, particularly targeting new geographic regions and healthcare sectors. The funding received will be utilized to bolster these development efforts, ensuring that DoseMe continues to enhance its product offerings and maintain relevance in the evolving healthcare landscape.